Michael James Heriford is a pharmacist who is specialized in Oncology in Longview, Washington. Patients can reach him at 1230 7th Ave, Longview or contact him on 360-636-6226. Active license number of Michael James Heriford is PH00039084 for Oncology in Washington. Michael James Heriford is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Michael James Heriford speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Michael James Heriford
Specialization:
Oncology
Credentials:
R.PH.
Gender:
Male
Location:
1230 7th Ave, Longview, Washington, 98632-3166
Phone:
360-636-6226
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Michael James Heriford are as mentioned below.
NPI Number:
1063623684
NPI Enumeration Date:
25 May, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Michael James Heriford are as mentioned below.
Specialization
License Number
State
Status
Oncology
PH00039084
Washington
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
215 Salmonberry Ln, Longview, Washington
Zip:
98632-9187
Phone Number:
--
Fax Number:
--
Patients can reach Michael James Heriford at 1230 7th Ave, Longview, Washington or can call on phone at 360-636-6226.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.